The Xconomy team will soon be heading over to Biogen Idec for our big evening event on the 20-year outlook for the San Diego life sciences cluster.
This sold-out gathering will bring together some life sciences visionaries to share their thoughts on San Diego biotech that go way beyond next month or next quarter. The highlight will be a discussion moderated by John Mendlein of Fate Therapeutics, along with panelists Paul Schimmel of The Scripps Research Institute, Dan Bradbury of Amylin Pharmaceuticals, Rusty Gage of the Salk Institute for Biological Studies. We will then hear some brief “burst” presentations from some of the potentially transformative life sciences startups in the region, which will segue into the networking portion of the evening.
Thanks to the many people who have helped make this happen. The list includes the event host, Biogen Idec; and event sponsors Fish & Richardson, Biogen Idec New Ventures, and Halloran Consulting Group. Of course, we’re grateful for help from our event partner, BIOCOM. And we can’t forget the support from our underwriters: Alexandria Real Estate Equities, Latham & Watkins, Biogen Idec, and the Science & Technology Directorate of the U.S. Department of Homeland Security.
I get to ask questions pretty much all day in my job as a journalist, but tonight my role is to be the emcee, helping you direct your questions to this distinguished panel. So come ready to think big about the long-term future for San Diego biotech. And be sure to stick around for some refreshments afterward to keep the conversation going.
